Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimized APT in ACS Patients with Non-predominant CAD After PCI
NCT04338919Unknown
- Sponsor
- Fujian Medical University
- Start
- Apr 2020
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of ticagrelor in acute coronary syndrome (ACS), sponsored by Fujian Medical University. Primary endpoint: Major cardiovascular and cerebrovascular adverse events at 12 months. Status: unknown.
02
Drugs
ticagrelor
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on NCT04338919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04338919.